A stealth-mode startup backed by one of Boston’s biggest venture capital firms, Flagship Pioneering, is planning to graduate from shared lab space to a much larger leased lab in Kendall Square, and is expecting to more than triple its staff by 2020, according to new details made public for the first time Thursday.

The company — still referred to by its stealth-mode moniker “VL49” — is one of several new startups trying to leverage three buzzy technologies: artificial intelligence, CRISPR, and single-celled sequencing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy